Porownywarka
Gonadorelin vs Leuprolide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Gonadorelin | Leuprolide |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | GnRH, LHRH, Factrel | Lupron, Eligard, Leuprorelin |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
| FDA Approved - Multiple indications
|
| Czego oczekiwac | Hormone stimulation, fertility, TRT support | Prostate cancer, endometriosis, hormone suppression |
| Jak dziala | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. | Leuprolide is reported to act as a high-potency agonist at pituitary GnRH receptors. Initial receptor activation can briefly increase LH, FSH, and sex hormones, but sustained exposure desensitizes the pituitary GnRH response and suppresses downstream gonadal hormone production. The source links this hormone-lowering effect to use in androgen- or estrogen-sensitive conditions and notes that the early flare can be clinically relevant. |
| Typowe dawkowanie | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump | Variable - depends on formulation · Daily, monthly, or every 3-6 months |
| Dawkowanie z badań | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump | 7.5mg monthly depot · Months to years depending on indication · Intramuscular or subcutaneous depot injection |
| Typowy czas trwania | Single dose (diagnostic) or ongoing (therapeutic) | Months to years depending on indication |
| Podanie | IV, subcutaneous, or pulsatile pump | Intramuscular or subcutaneous depot injection |
| Timing | Morning or as clinically directed With or without food | Morning or as directed With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+5 więcej
|
| Podsumowanie researchu | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. | The supplied evidence frames Leuprolide as a long-established FDA-approved GnRH agonist with clinical use rather than as an exploratory research peptide. It reports approval dating to 1989 and describes evidence in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The same source emphasizes that its benefits are tied to reversible suppression of sex-hormone production, while many important adverse effects arise from that low-hormone state, including hot flashes and bone-density concerns with longer exposure. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.